Clinical Trial Update: Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating erlotinib with or without investigational drug U3-1287 in advanced non-small cell lung cancer has completed, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• U3-1287

Snippet

Sponsor: Daiichi Sankyo | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-16